Daniel Z. Wang

Statistics

Publications

Citations

1.3K

H-Index

Active since

1997

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Daniel Z. Wang is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in finasteride therapy, benign prostatic enlargement, and prostate disorders.

Publications per year

1997–1999

Publications

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia

John D. McConnell, Reginald C. Bruskewitz, Patrick Walsh et al. · New England Journal of Medicine · 1998 · 1.1K citations · Full text

Medicine, Surgery, Urology +17

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia

Reginald C. Bruskewitz, Cynthia J. Girman, Jackson E. Fowler et al. · Urology · 1999 · 91 citations

Medicine, Pharmacotherapy, Urology +12

MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen<sup>1</sup>

Jules I. Schwartz, Wesley Tanaka, Daniel Z. Wang et al. · The Journal of Clinical Endocrinology & Metabolism · 1997 · 37 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen

Jules I. Schwartz, Wesley Tanaka, Daniel Z. Wang et al. · Obstetrical & Gynecological Survey · 1997 · 12 citations

Life Sciences, Biochemistry, Endocrinology +6

1–4 of 4